Literature DB >> 21387169

Expression of CD38 with intracellular enzymatic activity: a possible explanation for the insulin release induced by intracellular cADPR.

Yasuhiko Ohta1, Akira Kitanaka, Keichiro Mihara, Osamu Imataki, Hiroaki Ohnishi, Terukazu Tanaka, Tomohiko Taminato, Yoshitsugu Kubota.   

Abstract

CD38 is a transmembrane glycoprotein expressed in multiple cell types, including pancreatic β cells. It can serve as an enzyme that catalyzes the metabolism of two different Ca(2+)-mobilizing compounds, cyclic adenosine diphosphoribose (cADPR) and nicotinic acid adenine dinucleotide phosphate. One of these metabolites, cADPR, is known to be involved in glucose-induced insulin secretion from pancreatic β cells. Although the essential role of CD38 for endogenous cADPR synthesis has been established, the relationship between the proposed extracellular enzymatic activity of CD38 and the intracellular Ca(2+) modulation caused by the intracellular cADPR accumulation has not yet been fully explained. For a better understanding of the role of CD38 in the insulin secretion machinery, analysis of the intracellular localization of this molecule in pancreatic β cells is essential. In an attempt to provide a method to probe the N-terminal and C-terminal of CD38 separately, we generated an insulin-secreting MIN6 murine pancreatic β cell line expressing a human CD38 bearing an N-terminal FLAG epitope tag. We found a weak but consistent expression of the FLAG epitope outside of the cells, indicating the presence of a small amount of CD38 with cytoplasmic enzymatic activity. MIN6 cells transfected with human CD38 exhibited increased glucose-induced insulin release. In addition, anti-FLAG cross-linking further enhanced the insulin release, suggesting that the N-terminal of CD38 expressed on the cell surface functions as a receptor for an unknown ligand and triggers positive signals for insulin secretion.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21387169     DOI: 10.1007/s11010-011-0765-x

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  37 in total

1.  Identification and characterization of nuclear CD38 in the rat spleen.

Authors:  Keng Meng Khoo; Chan Fong Chang
Journal:  Int J Biochem Cell Biol       Date:  2002-01       Impact factor: 5.085

2.  Paracrine roles of NAD+ and cyclic ADP-ribose in increasing intracellular calcium and enhancing cell proliferation of 3T3 fibroblasts.

Authors:  L Franco; E Zocchi; C Usai; L Guida; S Bruzzone; A Costa; A De Flora
Journal:  J Biol Chem       Date:  2001-03-27       Impact factor: 5.157

3.  CD38-mediated signaling events in murine pro-B cells expressing human CD38 with or without its cytoplasmic domain.

Authors:  A Kitanaka; T Suzuki; C Ito; H Nishigaki; E Coustan-Smith; T Tanaka; Y Kubota; D Campana
Journal:  J Immunol       Date:  1999-02-15       Impact factor: 5.422

Review 4.  The CD38/cyclic ADP-ribose system: a topological paradox.

Authors:  A De Flora; L Guida; L Franco; E Zocchi
Journal:  Int J Biochem Cell Biol       Date:  1997-10       Impact factor: 5.085

5.  CD38 ligation in human B cell progenitors triggers tyrosine phosphorylation of CD19 and association of CD19 with lyn and phosphatidylinositol 3-kinase.

Authors:  A Kitanaka; C Ito; E Coustan-Smith; D Campana
Journal:  J Immunol       Date:  1997-07-01       Impact factor: 5.422

Review 6.  Recent advances in the Okamoto model: the CD38-cyclic ADP-ribose signal system and the regenerating gene protein (Reg)-Reg receptor system in beta-cells.

Authors:  Hiroshi Okamoto; Shin Takasawa
Journal:  Diabetes       Date:  2002-12       Impact factor: 9.461

7.  CD38 ligation inhibits normal and leukemic myelopoiesis.

Authors:  E Todisco; T Suzuki; K Srivannaboon; E Coustan-Smith; S C Raimondi; F G Behm; A Kitanaka; D Campana
Journal:  Blood       Date:  2000-01-15       Impact factor: 22.113

8.  A single protein immunologically identified as CD38 displays NAD+ glycohydrolase, ADP-ribosyl cyclase and cyclic ADP-ribose hydrolase activities at the outer surface of human erythrocytes.

Authors:  E Zocchi; L Franco; L Guida; U Benatti; A Bargellesi; F Malavasi; H C Lee; A De Flora
Journal:  Biochem Biophys Res Commun       Date:  1993-11-15       Impact factor: 3.575

9.  The CD38-cyclic ADP-ribose signaling system in insulin secretion.

Authors:  H Okamoto
Journal:  Mol Cell Biochem       Date:  1999-03       Impact factor: 3.396

Review 10.  Physiological functions of cyclic ADP-ribose and NAADP as calcium messengers.

Authors:  H C Lee
Journal:  Annu Rev Pharmacol Toxicol       Date:  2001       Impact factor: 13.820

View more
  5 in total

Review 1.  Cyclic ADP-ribose and nicotinic acid adenine dinucleotide phosphate (NAADP) as messengers for calcium mobilization.

Authors:  Hon Cheung Lee
Journal:  J Biol Chem       Date:  2012-07-20       Impact factor: 5.157

2.  In vitro reprogramming of rat bmMSCs into pancreatic endocrine-like cells.

Authors:  Hong-Tu Li; Fang-Xu Jiang; Ping Shi; Tao Zhang; Xiao-Yu Liu; Xue-Wen Lin; Zhong-Yan San; Xi-Ning Pang
Journal:  In Vitro Cell Dev Biol Anim       Date:  2016-10-03       Impact factor: 2.416

Review 3.  CD38: A Potential Therapeutic Target in Cardiovascular Disease.

Authors:  Wanyun Zuo; Na Liu; Yunhong Zeng; Yaozhong Liu; Biao Li; Keke Wu; Yunbin Xiao; Qiming Liu
Journal:  Cardiovasc Drugs Ther       Date:  2021-08       Impact factor: 3.727

4.  Solid-phase synthesis of a new diphosphate 5-aminoimidazole-4-carboxamide riboside (AICAR) derivative and studies toward cyclic AICAR diphosphate ribose.

Authors:  Stefano D'Errico; Giorgia Oliviero; Nicola Borbone; Jussara Amato; Vincenzo Piccialli; Michela Varra; Luciano Mayol; Gennaro Piccialli
Journal:  Molecules       Date:  2011-09-21       Impact factor: 4.411

5.  Okamoto model for necrosis and its expansions, CD38-cyclic ADP-ribose signal system for intracellular Ca2+ mobilization and Reg (Regenerating gene protein)-Reg receptor system for cell regeneration.

Authors:  Hiroshi Okamoto; Shin Takasawa
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2021       Impact factor: 3.493

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.